[Translation] A single-center, open-label, randomized, single-dose, two-formulation, two-sequence, fasting and fed bioequivalence study of mianserin hydrochloride tablets in healthy subjects
Primary objective
To compare the differences in the extent and rate of absorption of Mianserin Hydrochloride Tablets (30 mg) produced by Shandong Jingwei Pharmaceutical Co., Ltd. and Mianserin Hydrochloride Tablets (30 mg, trade name: Tetramide®) certified by Organon Co., Ltd. in healthy adults under fasting and fed administration conditions, and to evaluate their bioequivalence.
Secondary objective
To evaluate the safety of Mianserin Hydrochloride Tablets (30 mg) produced by Shandong Jingwei Pharmaceutical Co., Ltd. and Mianserin Hydrochloride Tablets (30 mg, trade name: Tetramide®) certified by Organon Co., Ltd. in healthy adults under fasting and fed administration conditions.
[Translation] A multicenter, randomized, double-blind, double-dummy, active drug parallel controlled phase III clinical trial to evaluate the efficacy and safety of beclomethasone formoterol inhalation aerosol in patients with asthma
Primary objective: To evaluate the effectiveness of beclomethasone formoterol inhalation aerosol (Qi Er Chang®/FOSTER®) produced by Shandong Jingwei Pharmaceutical Co., Ltd. in the treatment of Chinese asthma patients, using beclomethasone formoterol inhalation aerosol (Qi Er Chang®/FOSTER®) produced by Chiesi Farmaceutici SPA as a positive control.
Secondary objective: To evaluate the safety of beclomethasone formoterol inhalation aerosol produced by Shandong Jingwei Pharmaceutical Co., Ltd. in the treatment of Chinese asthma patients.
Primary objectives:
(1) To evaluate the bioavailability of XJN010 nasal spray relative to carbocycline sustained-release tablets in healthy Chinese subjects;
(2) To evaluate the pharmacokinetic (PK) characteristics of XJN010 nasal spray after a single dose in healthy Chinese subjects.
Secondary objectives:
To evaluate the safety of XJN010 nasal spray after a single dose in healthy Chinese subjects.
100 Clinical Results associated with Jewim Pharmaceutical (Shandong) Co., Ltd
Login to view more data
0 Patents (Medical) associated with Jewim Pharmaceutical (Shandong) Co., Ltd
Login to view more data
4
Literatures (Medical) associated with Jewim Pharmaceutical (Shandong) Co., Ltd
28 Oct 2024·ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES
The crystal structure of (Z)-3′-(2-(1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylicacid ─ methanol (1/1), C26H26N4O5
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.